Literature DB >> 18651123

[Clinical network structures in uro-oncology. A model for the future?].

A Heidenreich1, F Finke.   

Abstract

Systemic medical treatment (androgen deprivation, immunomodulatory therapy, and cytotoxic therapy) is an integral part of urology when managing patients with advanced or metastatic cancer of the urogenital tract. In the past, however, an increasing number of urologists in private practice and urological institutions have transferred this competence to neighbouring disciplines, so a thorough education of the young urologist in the field of uro-oncology is highly jeopardized. We present a regional, cooperative network structure between urologists in private practice and in hospitals, which has resulted in a standardization of indication, realization, documentation, quality control, and supportive strategies for systemic medical treatment of patients with metastatic urologic cancer. Furthermore, a well-functioning and cooperative platform was established for the recruitment and realization of clinical trials, which could serve as a model for the structure of future cooperation among German urologists in private practice and in hospitals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651123     DOI: 10.1007/s00120-008-1823-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

Review 1.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Authors:  M S Aapro; D A Cameron; R Pettengell; J Bohlius; J Crawford; M Ellis; N Kearney; G H Lyman; V C Tjan-Heijnen; J Walewski; D C Weber; C Zielinski
Journal:  Eur J Cancer       Date:  2006-06-05       Impact factor: 9.162

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Authors:  Johanna N Timmer-Bonte; Theo M de Boo; Hans J Smit; Bonne Biesma; Frank A Wilschut; Samia A Cheragwandi; Arien Termeer; Cornelis A Hensing; Janine Akkermans; Eddy M Adang; Geeben P Bootsma; Vivianne C Tjan-Heijnen
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

Review 5.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Authors:  C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran
Journal:  Eur J Cancer       Date:  2006-12-19       Impact factor: 9.162

6.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

7.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

8.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

View more
  3 in total

1.  [Effects of the new further training regulations on the training behavior of assistant doctors].

Authors:  T Enzmann; F Benzing
Journal:  Urologe A       Date:  2009-08       Impact factor: 0.639

2.  [Residents training in private practice : Conflicts between circumstances, willingness, and reality].

Authors:  J Salem; H Borgmann; J Bründl; E-M Lausenmeyer; V Lent; A Schroeder; A Heidenreich
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

3.  "We talk it over"--mixed-method study of interdisciplinary collaborations in private practice among urologists and oncologists in Germany.

Authors:  Sandra Beermann; Denny Chakkalakal; Rebecca Muckelbauer; Lothar Weißbach; Christine Holmberg
Journal:  BMC Cancer       Date:  2014-10-04       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.